Suppr超能文献

脂肪性肝病的纵向临床结局与死亡率:一项荟萃分析。

Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis.

作者信息

Kim Do Han, Ko Donghyun, Danpanichkul Pojsakorn, Ho Glenn Jun Kit, Tan Faith Xin Ning, Sasikumar N Apoorva, Tham Ethan Kai Jun, Huang Daniel Q, Syn Nicholas, Zheng Ming-Hua, Kawaguchi Takumi, Sumida Yoshio, Nakajima Atsushi, Takahashi Hirokazu, Noureddin Mazen, Ng Cheng Han, Muthiah Mark D, Wijarnpreecha Karn

机构信息

Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY.

Department of Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Conn.

出版信息

Am J Med. 2025 Apr 30. doi: 10.1016/j.amjmed.2025.04.027.

Abstract

INTRODUCTION

The updated consensus introduces "steatotic liver disease" as an umbrella term for all patients with hepatic steatosis, with specific subtypes such as metabolic dysfunction-associated steatotic liver disease (MASLD), MetALD (MASLD with moderate alcohol intake), and alcohol-associated liver disease. Understanding the characteristics and long-term outcomes of these subtypes is essential.

METHODS

A systematic review and meta-analysis examined studies published between January 2023 and August 2024 in MEDLINE and EMBASE on liver-related events, cardiovascular outcomes, and mortality across steatotic liver disease subtypes.

RESULTS

A total of 13 studies, involving 17.6 million patients were included. Of these, 6.8 million individuals were diagnosed with steatotic liver disease. Subtype analysis revealed a significant increase in liver-related events and composite cardiovascular outcomes across all steatotic liver disease subtypes compared to non-steatotic liver disease. Patients with MetALD and alcohol-associated liver disease were associated with a higher risk of all-cause mortality when compared to non-steatotic liver disease. Compared to MASLD, patients with MetALD and alcohol-associated liver disease significantly elevated the risk of liver-related events and individuals with alcohol-associated liver disease were associated with increased risk of all-cause mortality. Sensitivity analysis demonstrated that certain mortality outcomes were no longer significant.

CONCLUSION

Individuals across steatotic liver disease face an elevated risk of liver-related events, liver cancer, and cardiovascular outcomes. For liver-related events, the risk is progressively higher across MASLD, MetALD, and alcohol-associated liver disease, respectively. Misclassification may be introduced when using different diagnostic methods, leading to changes in outcomes. These findings validate the impact of the new classification in predicting outcomes.

摘要

引言

更新后的共识引入了“脂肪性肝病”这一术语,作为所有肝脂肪变性患者的统称,包括特定亚型,如代谢功能障碍相关脂肪性肝病(MASLD)、代谢性酒精性肝病(MetALD,即中度饮酒的MASLD)和酒精性肝病。了解这些亚型的特征和长期预后至关重要。

方法

一项系统评价和荟萃分析,检索了2023年1月至2024年8月期间发表在MEDLINE和EMBASE上的关于脂肪性肝病各亚型的肝脏相关事件、心血管结局和死亡率的研究。

结果

共纳入13项研究,涉及1760万患者。其中,680万人被诊断为脂肪性肝病。亚型分析显示,与非脂肪性肝病相比,所有脂肪性肝病亚型的肝脏相关事件和复合心血管结局均显著增加。与非脂肪性肝病相比,MetALD和酒精性肝病患者的全因死亡率风险更高。与MASLD相比,MetALD和酒精性肝病患者的肝脏相关事件风险显著升高,且酒精性肝病患者的全因死亡率风险增加。敏感性分析表明,某些死亡率结局不再显著。

结论

脂肪性肝病患者面临肝脏相关事件、肝癌和心血管结局的风险升高。对于肝脏相关事件,MASLD、MetALD和酒精性肝病的风险依次逐渐升高。使用不同诊断方法可能会导致分类错误,从而改变结局。这些发现证实了新分类在预测结局方面的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验